Additionally, STM2457, a METTL3/METTL14 inhibitor, exhibited potent antileukemic effects in preclinical AML models, highlighting the feasibility of targeting m6A writers for cancer therapy [108]. This evidence concerns the gene METTL3 and acute myeloid leukemia.